Multicenter, randomized, double-blind clinical trial to evaluate efficacy and safety of combined glucosamine sulfate and chondroitin sulfate capsules for treating knee osteoarthritis

• Published in: Advances in rheumatology (London, England) Vol. 58; no. 1; p. 41
• Main Authors: Lomonte, Andrea Barranjard Vannucci, Mendonça, José Alexandre, de Castro Brandão, Gilberto, Castro, Marise Lazaretti
• Format: Journal Article
• Language: English
• Published: England BioMed Central 05-12-2018; Sociedade Brasileira de Reumatologia; BMC
• Subjects: Adverse events; Analgesics; Arthritis; Chondroitin; Chondroitin sulfate; Clinical trials; Double-blind studies; Drug dosages; Glucosamine; Knee; Laboratories; Osteoarthritis; Pain; Patients; Population; RHEUMATOLOGY; Safety; Knee; Glucosamine; Pain; Osteoarthritis; Chondroitin
• ISSN: 2523-3106; 2523-3106
• DOI: 10.1186/s42358-018-0041-9

To compare the efficacy and safety of a new fixed dose combination of glucosamine sulfate and chondroitin sulfate capsules (GS/CS) versus the fixed dose combination of glucosamine hydrochloride and chondroitin sulfate (Cosamin DS®) in capsules in patients with osteoarthritis (OA) of the knee.
Multicenter, randomized, double-blind study. Participants with knee OA Kellgren-Lawrence grades 1 to 3 and VAS of symptoms ≥4 cm were randomized to receive GS/CS or Cosamin DS® over 12 weeks. The primary efficacy endpoint was the evaluation of the analgesic efficacy by the investigator. Secondary efficacy endpoints included: joint pain and swelling, investigator efficacy of the medication, and the use of rescue medication. Adverse events and drug tolerability were analyzed.
One hundred patients were randomized, and 50 patients were allocated to each group. The analgesic efficacy evaluated by the investigator in the GS/CS group was 88.9, 95%CI: 75.2, 95.8% and in the Cosamin DS® group was 85.4%; 95%CI: 70.1, 93.4%. The mean reduction in the pain intensity was significant in both groups (p < 0.001), with no difference between them. The primary efficacy analysis demonstrated the non-inferiority of the GS/CS group compared with the Cosamin DS® group; the lower limit of the 90% confidence interval (CI) between the two groups (- 8.39%) was higher than the established margin of non-inferiority of - 10.00%. Improvement in other efficacy outcomes was observed, again without differences between groups. Adverse events were similar between groups and both presented good tolerability.
The new fixed-dose formulation of GS/CS is effective in treating knee OA, presenting a good safety and tolerability profile.
( https://clinicaltrials.gov/ct2/show/NCT00955552?term=NCT00955552&rank=1 ; ClinicalTrials.gov ; register number NCT00955552; First randomized patient: 08/17/2010).